Health Care/Hospital
TCI Biotech to Showcase Leadership as the "Liquid Expert" at SupplySide Global 2025, Featuring Clinically-Proven Innovations for Weight Management and Metabolic Health
LAS VEGAS, Oct. 28, 2025 /PRNewswire/ -- TCI Biotech is staking its claim as the "Liquid Expert" of the wellness industry, a title it aims to cement at SupplySide Global 2025. Its core philosophy is that in a crowded wellness landscape, clinical validation and technological superiority, not just ...
2025-10-28 22:00
1149
Noul Supplies AI Diagnostic Platform miLab™ to Charité, Europe's Leading University Hospital
* Prestigious Nobel Prize–winning institution confirms adoption of miLab™ following clinical evaluation * "A milestone signaling broader adoption in advanced global healthcare markets" YONGIN, South Korea, Oct. 28, 2025 /PRNewswire/ -- Noul Co., Ltd.(CEO David Lim), an AI-driven blood and can...
2025-10-28 21:00
859
Fosun Pharma Announces 2025Q3 Financial Results
Innovative Achievements Continue to Come to Fruition, Revenue from Innovative Drugs ExceedingRMB6,700 Million in The First Three Quarters of 2025 SHANGHAI, Oct. 28, 2025 /PRNewswire/ -- On October 28, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "the Group"; SSE: 60019...
2025-10-28 20:11
1820
Myrio Therapeutics Announces Collaboration with Leading Research Institutions to Advance Solid Tumor T cell Immunotherapeutics
* Myrio Therapeutics, the University of Pennsylvania Perelman School of Medicine, and NYU Langone Health have entered a research collaboration to accelerate the development of next-generation T cell immunotherapies * Partnership with T cell experts Daniel J Powell Jr., PhD, and Mark Yarmarkov...
2025-10-28 19:35
773
WuXi AppTec Looks to Extend CRDMO Platform to Saudi Arabia as It Signs Strategic MoUs with NEOM and Ministry of Health
SHANGHAI, Oct. 28, 2025 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today announced it has signed two strategic memoranda of understanding (MoUs) with NEOM, the sustainable region under development in northw...
2025-10-28 17:00
1463
Samsung Biologics reports third quarter 2025 financial results
* Recorded Q3'25 consolidated revenue of KRW 1,660.2 billion * Recorded Q3'25 consolidated operating profit of KRW 728.8 billion * Delivered consistent performance through stable capacity ramp-up and strengthened global partnerships INCHEON, South Korea, Oct. 28, 2025 /PRNewswire/ -- Samsung...
2025-10-28 14:50
1333
Fibronostics Acquires Stone Clinical Laboratories to Advance MASH/MASLD Diagnostics
Acquisition expands U.S. lab operations and accelerates innovation in non-invasive diagnostics for metabolic and liver diseases. NEW ORLEANS, Oct. 27, 2025 /PRNewswire/ -- Fibronostics, a global leader in non-invasive diagnostics for metabolic and liver diseases, today announced the completion o...
2025-10-27 22:46
1020
BioDlink Completes First International Shipment of Bevacizumab to Colombia
* Bevacizumab is a targeted therapy used to treat lung and colorectal cancers, both among the top three cancers ranked by death inColombia[1]. * This inaugural shipment—dispatched around two months after Colombia's marketing approval—demonstrates the company's efficiency, while validating its ...
2025-10-27 20:30
1010
National Center of Technology Innovation for Dairy Debuts at the IDF World Dairy Summit, Showcasing Innovation to Drive Sustainability
SANTIAGO, Chile, Oct. 27, 2025 /PRNewswire/ -- The highly anticipated 2025 IDF World Dairy Summit took place fromOctober 20 to 23 in Santiago, Chile. Drawing global attention, the event served as an important barometer for the future of the dairy industry. Liu Chunxi, Chairman of the National Ce...
2025-10-27 19:23
1121
Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner
SYDNEY, Oct. 27, 2025 /PRNewswire/ -- Kazia Therapeutics Limited ("Kazia" or the "Company") today announced its intention to request and hold a follow-up Type C meeting with the U.S. Food & Drug Administration (FDA) to discuss overall survival (OS) findings in newly diagnosed glioblastoma (GBM) p...
2025-10-27 19:15
1812
Daewoong Pharmaceutical: Third IDMC Reaffirms Safety of Bersiporocin and Recommends Continuation of Global Phase 2 Clinical Trial
* Third Independent Data Monitoring Committee (IDMC) review confirms safety and continuation of the study * 94 patients enrolled out of 102 planned across Korea and the U.S. * Interim baseline characteristics to be presented at the 2025 KATRD International Conference SEOUL, South Korea, Oct...
2025-10-27 19:00
1029
MINISH Technology Has Successfully Concluded Its First U.S. MINISH Veneers Course, Certifying 22 Dentists
SEOUL, South Korea, Oct. 27, 2025 /PRNewswire/ -- Health-tech company MINISH
Technology Inc. announced on the 27th that 22 dentists completed its 15th
MINISH Course, the first session held for local practitioners inthe United
States.
2025-10-27 14:58
1001
Innovent's Mazdutide Shows Superiority in Glycemic Control with Weight Loss over Semaglutide in a Head-to-head Phase 3 Clinical Trial DREAMS-3
* The proportion of participants achieving HbA1c < 7.0% and a ≥10% reduction in body weight from baseline was 48.0% in the mazdutide group and 21.0% in the semaglutide group * DREAMS-3 is the world's first Phase 3 clinical trial of a GCG/GLP-1 dual receptor agonist to conduct a head-to-head c...
2025-10-27 08:00
1148
WuXi AppTec Achieves Strong Double-Digit Growth in Revenue and Profit for Q1-Q3 2025 Backlog for Continuing Operations Up 41.2% YoY Further Raises 2025 Full-year Guidance
* Q3 Total Revenue: RMB12.06 Billion, Up 15.3% YoY; * Revenue from Continuing Operations[1] Reached RMB12.04 Billion, Up 19.7% YoY * Q1-Q3 Total Revenue: RMB32.86 Billion, Up 18.6% YoY; * Revenue from Continuing Operations Reached RMB32.45 Billion, Up 22.5% YoY * Q1-Q3 Net Profit Attributa...
2025-10-26 15:53
4265
Cardiovalve Completes TARGET Study Enrollment for CE Registration Study for Tricuspid Valve Replacement
The Company Advances Toward European CE Mark Submission with 150 Patients Enrolled; On Track for 2027 Commercial Launch HANGZHOU, China, Oct. 25, 2025 /PRNewswire/ -- Venus Medtech (Hangzhou) Inc. (2500.HK, hereinafter referred to as the "Company") today announced the successful completion of pa...
2025-10-25 15:00
2509
Breathe Easy This Fall: VARON Supports Respiratory Wellness During Seasonal Change
NEW YORK, Oct. 24, 2025 /PRNewswire/ -- As cooler temperatures and shifting air quality arrive, many families notice changes in their breathing. Dry air, allergens, and sudden cold snaps can worsen conditions like asthma or COPD, making respiratory health a top priority during the season. To h...
2025-10-25 08:00
1714
Beyond Recovery: QUINEAR QN-071A Brings Professional Compression Therapy Home for Holiday Deals
NEW YORK, Oct. 24, 2025 /PRNewswire/ -- When recovery becomes the new performance edge. True progress doesn't happen during exertion — it begins in recovery. For years, QUINEAR has led the evolution of professional-grade compression systems, making clinical technology accessible to everyday athl...
2025-10-25 00:07
1567
Terumo Interventional Systems Announces Its New OPUSWAVE® Dual Sensor Imaging System and DualView® Imaging Catheter Receive FDA 510(k) Clearance
* OPUSWAVE Imaging System combines OFDI and IVUS into a single catheter, providing significant potential to reduce procedural time and costs in treating coronary artery disease * DualView imaging catheter offers a 150mm maximum pullback length, a 2.6 Fr. imaging profile, 6 Fr. guide compatibi...
2025-10-24 20:00
1178
Global Launch Event for iza-bren Phase III Nasopharyngeal Carcinoma Research Results Successfully Held, Streamed on ESMO Official Website
SHANGHAI, Oct. 24, 2025 /PRNewswire/ -- At 15:00 Beijing Time (09:00 am Berlin Time) onOctober 20, the "Global Launch Event for Iza-bren (EGFR×HER3 Bispecific ADC) Nasopharyngeal Carcinoma BL-B01D1-303 Research Results" was held at the venue of the 2025 European Society for Medical Oncology (ESMO...
2025-10-24 16:40
929
HanchorBio Presents Phase 1 HCB101 Clinical Results at FACO 2025 Demonstrating Safety and Early Antitumor Activity
FACO 2025 presentation highlights HCB101's favorable safety, strong receptor occupancy, and confirmed responses in patients with advanced cancers. TAIPEI, SHANGHAI, and SAN FRANCISCO, Oct. 23, 2025 /PRNewswire/ -- HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advanci...
2025-10-24 07:30
1787
Week's Top Stories
Most Reposted
iQIYI LAND Yangzhou to Open on February 8, Marking New Chapter in China's Immersive Entertainment Scene
[Picked up by 276 media titles]
2026-01-01 10:00
ACEN completes transition to 100% renewable energy
[Picked up by 274 media titles]
2025-12-29 18:53Vietnam's Newest EDM Destination, APLUS SAIGON, Debuts With Star-Studded Soft Opening Weekends Featuring Dombresky and Argy
[Picked up by 273 media titles]
2025-12-30 20:12
CYFIRMA's 2025 Impact Recap Showcases DeCYFIR, Preemptive External Threat Landscape Management Platform, Delivering Measurable Global Defense Against Emerging Threats
[Picked up by 264 media titles]
2025-12-29 09:00
ChinaAMC launches Depository Receipts of two Chinese flagship ETFs in Thai exchange
[Picked up by 260 media titles]
2025-12-29 14:27Most Read
China Daily Launches "China Bound" -- An English-Language Smart-Tourism Service Platform for International Travelers
2026-01-01 17:04
7511
